Paul Phillips
Concepts (291)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diplopia | 8 | 2024 | 20 | 2.300 |
Why?
| | Exotropia | 7 | 2023 | 8 | 2.030 |
Why?
| | Pseudotumor Cerebri | 7 | 2024 | 23 | 1.910 |
Why?
| | Oculomotor Muscles | 5 | 2019 | 20 | 1.900 |
Why?
| | Ocular Motility Disorders | 5 | 2018 | 16 | 1.860 |
Why?
| | Ophthalmologic Surgical Procedures | 4 | 2019 | 21 | 1.780 |
Why?
| | Papilledema | 7 | 2026 | 27 | 1.700 |
Why?
| | Vision, Low | 3 | 2022 | 9 | 1.620 |
Why?
| | Optic Nerve | 6 | 2014 | 39 | 1.580 |
Why?
| | Optic Disk | 2 | 2023 | 20 | 1.330 |
Why?
| | Intracranial Pressure | 5 | 2019 | 29 | 1.310 |
Why?
| | Magnetic Resonance Imaging | 15 | 2023 | 1507 | 1.260 |
Why?
| | Ophthalmology | 3 | 2025 | 34 | 1.210 |
Why?
| | Hypopituitarism | 4 | 2014 | 16 | 1.180 |
Why?
| | Oculomotor Nerve Diseases | 3 | 2025 | 6 | 1.150 |
Why?
| | Eye Abnormalities | 4 | 2023 | 24 | 1.130 |
Why?
| | Child | 33 | 2026 | 7194 | 1.080 |
Why?
| | Strabismus | 5 | 2019 | 14 | 1.070 |
Why?
| | Intracranial Hypertension | 3 | 2019 | 31 | 0.970 |
Why?
| | Pituitary Gland | 3 | 2014 | 87 | 0.960 |
Why?
| | Vision, Binocular | 4 | 2019 | 6 | 0.930 |
Why?
| | Optic Nerve Diseases | 3 | 2023 | 21 | 0.900 |
Why?
| | Humans | 73 | 2026 | 52441 | 0.870 |
Why?
| | Vision Disorders | 4 | 2026 | 61 | 0.770 |
Why?
| | Vision Screening | 1 | 2022 | 11 | 0.770 |
Why?
| | Fixation, Ocular | 3 | 2019 | 12 | 0.760 |
Why?
| | Abducens Nerve Diseases | 2 | 2024 | 7 | 0.740 |
Why?
| | Retinal Hemorrhage | 4 | 2026 | 15 | 0.730 |
Why?
| | Eye Diseases, Hereditary | 2 | 2017 | 5 | 0.710 |
Why?
| | Tomography, Optical Coherence | 5 | 2022 | 110 | 0.700 |
Why?
| | Dyslexia | 2 | 2018 | 44 | 0.670 |
Why?
| | Child, Preschool | 22 | 2026 | 4046 | 0.650 |
Why?
| | Distance Perception | 1 | 2019 | 3 | 0.640 |
Why?
| | Male | 39 | 2026 | 26874 | 0.610 |
Why?
| | Postoperative Complications | 3 | 2015 | 1065 | 0.590 |
Why?
| | Orthoptics | 1 | 2018 | 1 | 0.580 |
Why?
| | Female | 38 | 2026 | 28277 | 0.550 |
Why?
| | Visual Acuity | 9 | 2022 | 144 | 0.520 |
Why?
| | Apraxias | 3 | 2013 | 9 | 0.510 |
Why?
| | Cavernous Sinus | 2 | 2011 | 15 | 0.510 |
Why?
| | Eyeglasses | 3 | 2023 | 9 | 0.480 |
Why?
| | Adolescent | 14 | 2024 | 6713 | 0.470 |
Why?
| | Diagnosis, Differential | 9 | 2018 | 1028 | 0.460 |
Why?
| | Craniocerebral Trauma | 3 | 2026 | 63 | 0.450 |
Why?
| | Retrospective Studies | 15 | 2026 | 6694 | 0.430 |
Why?
| | Nervous System Diseases | 2 | 2005 | 96 | 0.430 |
Why?
| | Blindness | 3 | 2024 | 31 | 0.430 |
Why?
| | Infant | 13 | 2026 | 3709 | 0.420 |
Why?
| | Giant Cell Arteritis | 2 | 2025 | 14 | 0.400 |
Why?
| | Comprehension | 2 | 2024 | 114 | 0.390 |
Why?
| | Developmental Disabilities | 2 | 2013 | 125 | 0.390 |
Why?
| | Child Abuse | 2 | 2026 | 143 | 0.380 |
Why?
| | Meningitis, Cryptococcal | 1 | 2012 | 10 | 0.380 |
Why?
| | Blepharoptosis | 1 | 2012 | 12 | 0.370 |
Why?
| | Cryptococcus neoformans | 1 | 2012 | 26 | 0.370 |
Why?
| | Internet | 2 | 2024 | 262 | 0.360 |
Why?
| | Carotid Artery, Internal, Dissection | 1 | 2011 | 8 | 0.360 |
Why?
| | United States | 9 | 2026 | 5215 | 0.360 |
Why?
| | Brain Diseases | 2 | 2012 | 80 | 0.350 |
Why?
| | Intracranial Aneurysm | 1 | 2011 | 46 | 0.340 |
Why?
| | Tuberous Sclerosis | 1 | 2011 | 37 | 0.340 |
Why?
| | Neurofibromatosis 1 | 1 | 2010 | 34 | 0.330 |
Why?
| | Cross-Sectional Studies | 8 | 2025 | 1677 | 0.320 |
Why?
| | Optic Disk Drusen | 1 | 2009 | 3 | 0.300 |
Why?
| | Hemianopsia | 1 | 2009 | 4 | 0.300 |
Why?
| | Hydrocephalus | 2 | 2025 | 41 | 0.290 |
Why?
| | Cerebrospinal Fluid Shunts | 1 | 2008 | 19 | 0.290 |
Why?
| | Dyskeratosis Congenita | 1 | 2008 | 2 | 0.290 |
Why?
| | Cerebellum | 2 | 2013 | 129 | 0.280 |
Why?
| | Rhombencephalon | 1 | 2007 | 4 | 0.280 |
Why?
| | Adrenoleukodystrophy | 1 | 2007 | 2 | 0.280 |
Why?
| | Botulinum Toxins | 1 | 2007 | 4 | 0.270 |
Why?
| | Aged | 10 | 2025 | 10242 | 0.270 |
Why?
| | Membrane Proteins | 2 | 2024 | 344 | 0.270 |
Why?
| | Middle Aged | 10 | 2025 | 13133 | 0.250 |
Why?
| | Visual Pathways | 2 | 2023 | 11 | 0.250 |
Why?
| | Adult | 13 | 2026 | 14205 | 0.250 |
Why?
| | Vaccination | 2 | 2025 | 294 | 0.250 |
Why?
| | Prevalence | 3 | 2025 | 1016 | 0.250 |
Why?
| | Risk Factors | 7 | 2026 | 3971 | 0.240 |
Why?
| | Trochlear Nerve Diseases | 1 | 2025 | 1 | 0.240 |
Why?
| | Pre-Eclampsia | 1 | 2026 | 60 | 0.230 |
Why?
| | Fluorescein Angiography | 2 | 2022 | 35 | 0.230 |
Why?
| | Retinopathy of Prematurity | 1 | 2025 | 16 | 0.230 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 2025 | 28 | 0.230 |
Why?
| | Aortic Aneurysm | 1 | 2025 | 28 | 0.230 |
Why?
| | Muscarinic Agonists | 1 | 2024 | 10 | 0.220 |
Why?
| | Young Adult | 6 | 2026 | 4346 | 0.220 |
Why?
| | Pilocarpine | 1 | 2024 | 20 | 0.220 |
Why?
| | Carotid Stenosis | 1 | 2025 | 61 | 0.220 |
Why?
| | Cerebrospinal Fluid Pressure | 2 | 2016 | 3 | 0.220 |
Why?
| | Aqueous Humor | 1 | 2024 | 10 | 0.220 |
Why?
| | Retinal Artery Occlusion | 1 | 2024 | 11 | 0.220 |
Why?
| | Retinal Detachment | 1 | 2024 | 26 | 0.220 |
Why?
| | Socioeconomic Factors | 2 | 2026 | 609 | 0.220 |
Why?
| | Eye Diseases | 1 | 2024 | 33 | 0.210 |
Why?
| | Patient Education as Topic | 2 | 2024 | 317 | 0.210 |
Why?
| | Burns, Chemical | 1 | 2024 | 9 | 0.210 |
Why?
| | Consumer Health Information | 1 | 2024 | 19 | 0.210 |
Why?
| | Follow-Up Studies | 5 | 2024 | 2294 | 0.210 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2025 | 145 | 0.210 |
Why?
| | Eye Injuries | 1 | 2024 | 25 | 0.210 |
Why?
| | Retirement | 1 | 2023 | 16 | 0.200 |
Why?
| | Optic Chiasm | 1 | 2003 | 6 | 0.200 |
Why?
| | Optic Atrophy, Hereditary, Leber | 1 | 2003 | 5 | 0.200 |
Why?
| | Self Report | 1 | 2024 | 221 | 0.200 |
Why?
| | Patient Selection | 1 | 2024 | 269 | 0.200 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 14 | 0.190 |
Why?
| | Forecasting | 1 | 2023 | 151 | 0.190 |
Why?
| | Dementia | 1 | 2024 | 168 | 0.190 |
Why?
| | Meningeal Neoplasms | 1 | 2023 | 51 | 0.190 |
Why?
| | Charcot-Marie-Tooth Disease | 1 | 2022 | 7 | 0.190 |
Why?
| | Optic Atrophy | 1 | 2022 | 13 | 0.180 |
Why?
| | Central Nervous System Neoplasms | 1 | 2023 | 69 | 0.180 |
Why?
| | Anesthetics, Combined | 1 | 2001 | 2 | 0.180 |
Why?
| | Aged, 80 and over | 4 | 2025 | 3449 | 0.180 |
Why?
| | Proteomics | 1 | 2024 | 332 | 0.180 |
Why?
| | Anesthesia, Local | 1 | 2001 | 18 | 0.180 |
Why?
| | Brain Injuries | 1 | 2023 | 158 | 0.180 |
Why?
| | Ophthalmoscopy | 2 | 2013 | 17 | 0.180 |
Why?
| | Prospective Studies | 4 | 2019 | 2433 | 0.180 |
Why?
| | Macular Degeneration | 1 | 2021 | 28 | 0.170 |
Why?
| | Orbital Diseases | 1 | 2001 | 12 | 0.170 |
Why?
| | Vision Tests | 3 | 2023 | 13 | 0.170 |
Why?
| | Anesthetics, Local | 1 | 2001 | 77 | 0.170 |
Why?
| | Health Services Accessibility | 1 | 2025 | 444 | 0.170 |
Why?
| | Phacoemulsification | 1 | 2001 | 36 | 0.170 |
Why?
| | Choroiditis | 1 | 2020 | 9 | 0.170 |
Why?
| | Retinal Diseases | 1 | 2021 | 53 | 0.170 |
Why?
| | Multiple Sclerosis | 1 | 2021 | 72 | 0.160 |
Why?
| | Mutation | 3 | 2017 | 1331 | 0.160 |
Why?
| | Health Status Disparities | 1 | 2023 | 218 | 0.160 |
Why?
| | Reproducibility of Results | 3 | 2024 | 1223 | 0.160 |
Why?
| | Vitreoretinal Surgery | 1 | 2019 | 8 | 0.160 |
Why?
| | Healthcare Disparities | 1 | 2023 | 291 | 0.150 |
Why?
| | Carotid Artery Diseases | 1 | 1999 | 32 | 0.150 |
Why?
| | Arteriovenous Fistula | 1 | 1999 | 27 | 0.150 |
Why?
| | Crohn Disease | 1 | 2020 | 115 | 0.150 |
Why?
| | Laser Therapy | 1 | 2019 | 74 | 0.150 |
Why?
| | Sensitivity and Specificity | 2 | 2013 | 871 | 0.150 |
Why?
| | Imaging, Three-Dimensional | 1 | 2019 | 150 | 0.150 |
Why?
| | Astigmatism | 1 | 2018 | 5 | 0.140 |
Why?
| | Amblyopia | 1 | 2018 | 5 | 0.140 |
Why?
| | Mydriatics | 1 | 2018 | 12 | 0.140 |
Why?
| | Pupil | 1 | 2018 | 28 | 0.140 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2018 | 17 | 0.140 |
Why?
| | Obesity | 3 | 2016 | 1176 | 0.140 |
Why?
| | Convergence, Ocular | 1 | 2017 | 2 | 0.140 |
Why?
| | Accommodation, Ocular | 1 | 2017 | 3 | 0.140 |
Why?
| | Reading | 1 | 2018 | 76 | 0.140 |
Why?
| | Myopia | 1 | 2017 | 8 | 0.140 |
Why?
| | Glucose Transport Proteins, Facilitative | 1 | 2017 | 9 | 0.140 |
Why?
| | Keratoconus | 1 | 2017 | 4 | 0.140 |
Why?
| | Skin Diseases, Genetic | 1 | 2017 | 8 | 0.130 |
Why?
| | Heterozygote | 1 | 2017 | 89 | 0.130 |
Why?
| | Minocycline | 1 | 2017 | 15 | 0.130 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2018 | 62 | 0.130 |
Why?
| | Cornea | 1 | 2017 | 53 | 0.130 |
Why?
| | Joint Instability | 1 | 2017 | 43 | 0.130 |
Why?
| | Arteries | 1 | 2017 | 93 | 0.130 |
Why?
| | Equipment Failure | 2 | 2025 | 63 | 0.130 |
Why?
| | Carbonic Anhydrase Inhibitors | 1 | 2016 | 3 | 0.130 |
Why?
| | Syndrome | 1 | 2017 | 247 | 0.130 |
Why?
| | Acetazolamide | 1 | 2016 | 16 | 0.130 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2018 | 177 | 0.130 |
Why?
| | Depth Perception | 2 | 2005 | 4 | 0.120 |
Why?
| | Vascular Malformations | 1 | 2017 | 105 | 0.120 |
Why?
| | Nevus of Ota | 1 | 2014 | 2 | 0.110 |
Why?
| | Scleral Diseases | 1 | 2014 | 2 | 0.110 |
Why?
| | Chi-Square Distribution | 2 | 2005 | 292 | 0.110 |
Why?
| | Eye Neoplasms | 1 | 2014 | 8 | 0.110 |
Why?
| | Siblings | 1 | 2014 | 35 | 0.110 |
Why?
| | Functional Laterality | 1 | 2014 | 91 | 0.110 |
Why?
| | Sex Factors | 2 | 2016 | 735 | 0.100 |
Why?
| | Treatment Outcome | 3 | 2019 | 5508 | 0.100 |
Why?
| | Temporal Arteries | 2 | 2025 | 16 | 0.100 |
Why?
| | Cogan Syndrome | 1 | 2013 | 3 | 0.100 |
Why?
| | Kidney Diseases, Cystic | 1 | 2013 | 18 | 0.100 |
Why?
| | Cerebellar Diseases | 1 | 2013 | 17 | 0.100 |
Why?
| | Body Mass Index | 1 | 2016 | 701 | 0.100 |
Why?
| | Optic Nerve Neoplasms | 2 | 2004 | 7 | 0.100 |
Why?
| | Stroke | 1 | 2018 | 527 | 0.100 |
Why?
| | Retina | 1 | 2013 | 60 | 0.100 |
Why?
| | Case-Control Studies | 2 | 2005 | 1202 | 0.090 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2013 | 202 | 0.090 |
Why?
| | Myasthenia Gravis | 1 | 2012 | 18 | 0.090 |
Why?
| | Visual Fields | 2 | 2009 | 39 | 0.090 |
Why?
| | Orbit | 2 | 2003 | 24 | 0.090 |
Why?
| | Risk Assessment | 1 | 2016 | 1349 | 0.090 |
Why?
| | Incidence | 2 | 2025 | 1096 | 0.090 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 816 | 0.090 |
Why?
| | Sex Distribution | 2 | 2024 | 138 | 0.090 |
Why?
| | Acute Disease | 2 | 2021 | 384 | 0.080 |
Why?
| | Skin Neoplasms | 1 | 2014 | 496 | 0.080 |
Why?
| | Optic Nerve Injuries | 1 | 2009 | 8 | 0.080 |
Why?
| | Paranasal Sinuses | 1 | 2009 | 15 | 0.080 |
Why?
| | Decompression, Surgical | 1 | 2009 | 48 | 0.070 |
Why?
| | Endoscopy | 1 | 2009 | 126 | 0.070 |
Why?
| | Infant, Newborn | 2 | 2026 | 2871 | 0.070 |
Why?
| | Blood Transfusion | 1 | 2008 | 126 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 2 | 2009 | 1140 | 0.060 |
Why?
| | DNA, Mitochondrial | 2 | 2003 | 112 | 0.060 |
Why?
| | Age Factors | 2 | 2019 | 1120 | 0.060 |
Why?
| | Treatment Failure | 1 | 2025 | 117 | 0.060 |
Why?
| | Ophthalmic Solutions | 1 | 2024 | 19 | 0.060 |
Why?
| | Administration, Topical | 1 | 2024 | 62 | 0.060 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2024 | 10 | 0.060 |
Why?
| | Vitreous Body | 1 | 2024 | 18 | 0.060 |
Why?
| | Paracentesis | 1 | 2024 | 13 | 0.050 |
Why?
| | Bone Diseases, Developmental | 1 | 2024 | 17 | 0.050 |
Why?
| | Prognosis | 1 | 2010 | 2100 | 0.050 |
Why?
| | Eye Proteins | 1 | 2024 | 16 | 0.050 |
Why?
| | Methylprednisolone | 2 | 2018 | 40 | 0.050 |
Why?
| | Neuronal Ceroid-Lipofuscinoses | 1 | 2004 | 6 | 0.050 |
Why?
| | Chromosomes, Human, Pair 15 | 1 | 2004 | 9 | 0.050 |
Why?
| | Retinal Degeneration | 1 | 2004 | 9 | 0.050 |
Why?
| | Proportional Hazards Models | 1 | 2025 | 446 | 0.050 |
Why?
| | Propensity Score | 1 | 2024 | 160 | 0.050 |
Why?
| | Vitrectomy | 1 | 2024 | 61 | 0.050 |
Why?
| | Refraction, Ocular | 1 | 2023 | 7 | 0.050 |
Why?
| | Exons | 1 | 2004 | 101 | 0.050 |
Why?
| | Cultural Diversity | 1 | 2023 | 36 | 0.050 |
Why?
| | Molecular Chaperones | 1 | 2004 | 76 | 0.050 |
Why?
| | Hematoma, Subdural | 1 | 2023 | 13 | 0.050 |
Why?
| | Optic Atrophies, Hereditary | 1 | 2003 | 2 | 0.050 |
Why?
| | Schools, Medical | 1 | 2023 | 68 | 0.050 |
Why?
| | Chromosome Deletion | 1 | 2004 | 138 | 0.050 |
Why?
| | Hypertrophy | 1 | 2003 | 53 | 0.050 |
Why?
| | Mass Spectrometry | 1 | 2024 | 294 | 0.050 |
Why?
| | Biopsy | 2 | 2021 | 594 | 0.050 |
Why?
| | Faculty, Medical | 1 | 2023 | 92 | 0.050 |
Why?
| | DNA Mutational Analysis | 1 | 2003 | 179 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 239 | 0.050 |
Why?
| | Health Literacy | 1 | 2024 | 131 | 0.050 |
Why?
| | Electronic Health Records | 1 | 2024 | 274 | 0.050 |
Why?
| | Needlestick Injuries | 1 | 2001 | 2 | 0.050 |
Why?
| | Pituitary Hormones | 1 | 2001 | 18 | 0.050 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 177 | 0.050 |
Why?
| | Scotoma | 1 | 2021 | 6 | 0.040 |
Why?
| | Lens Implantation, Intraocular | 1 | 2001 | 25 | 0.040 |
Why?
| | Spinal Puncture | 2 | 2018 | 17 | 0.040 |
Why?
| | Fundus Oculi | 1 | 2021 | 24 | 0.040 |
Why?
| | Bupivacaine | 1 | 2001 | 29 | 0.040 |
Why?
| | Lidocaine | 1 | 2001 | 48 | 0.040 |
Why?
| | Mucormycosis | 1 | 2001 | 28 | 0.040 |
Why?
| | Graves Disease | 1 | 2001 | 19 | 0.040 |
Why?
| | Eye Infections, Fungal | 1 | 2001 | 20 | 0.040 |
Why?
| | Pilot Projects | 1 | 2023 | 725 | 0.040 |
Why?
| | Intravitreal Injections | 1 | 2020 | 33 | 0.040 |
Why?
| | Saccades | 1 | 2000 | 4 | 0.040 |
Why?
| | Pedigree | 1 | 2000 | 126 | 0.040 |
Why?
| | Aspergillosis | 1 | 2001 | 122 | 0.040 |
Why?
| | Arkansas | 1 | 2026 | 2013 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 186 | 0.040 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 521 | 0.040 |
Why?
| | Angiogenesis Inhibitors | 1 | 2020 | 183 | 0.040 |
Why?
| | Pandemics | 1 | 2024 | 580 | 0.040 |
Why?
| | Trochlear Nerve | 1 | 1999 | 1 | 0.040 |
Why?
| | Ophthalmoplegia | 1 | 1999 | 6 | 0.040 |
Why?
| | Postoperative Care | 1 | 2019 | 104 | 0.040 |
Why?
| | Cranial Nerve Diseases | 1 | 1999 | 16 | 0.040 |
Why?
| | Pregnancy | 1 | 2026 | 2642 | 0.040 |
Why?
| | Refractive Errors | 1 | 2018 | 6 | 0.040 |
Why?
| | Tropicamide | 1 | 2018 | 5 | 0.040 |
Why?
| | Cyclopentolate | 1 | 2018 | 5 | 0.040 |
Why?
| | Equipment Design | 1 | 2019 | 287 | 0.040 |
Why?
| | Phenylephrine | 1 | 2018 | 36 | 0.040 |
Why?
| | Drug Combinations | 1 | 2018 | 136 | 0.030 |
Why?
| | Phlebography | 1 | 2018 | 54 | 0.030 |
Why?
| | Corneal Topography | 1 | 2017 | 6 | 0.030 |
Why?
| | Corneal Pachymetry | 1 | 2017 | 6 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2004 | 643 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2017 | 25 | 0.030 |
Why?
| | Sexual Maturation | 1 | 2016 | 19 | 0.030 |
Why?
| | Age Distribution | 1 | 2016 | 176 | 0.030 |
Why?
| | Glucocorticoids | 1 | 2018 | 234 | 0.030 |
Why?
| | Morbidity | 1 | 2016 | 137 | 0.030 |
Why?
| | Disease Progression | 1 | 2018 | 870 | 0.030 |
Why?
| | Cytoskeletal Proteins | 1 | 2013 | 47 | 0.020 |
Why?
| | Abnormalities, Multiple | 1 | 2013 | 164 | 0.020 |
Why?
| | Recovery of Function | 1 | 2009 | 201 | 0.020 |
Why?
| | Brain | 2 | 2004 | 1337 | 0.010 |
Why?
| | Electroretinography | 1 | 2004 | 17 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2004 | 62 | 0.010 |
Why?
| | Neurologic Examination | 1 | 2004 | 73 | 0.010 |
Why?
| | Alleles | 1 | 2004 | 279 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2004 | 458 | 0.010 |
Why?
| | Electroencephalography | 1 | 2004 | 301 | 0.010 |
Why?
| | Hemorrhage | 1 | 2003 | 225 | 0.010 |
Why?
| | Skin | 1 | 2004 | 416 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2004 | 799 | 0.010 |
Why?
|
|
Phillips's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|